German drugmaker Boehringer Ingelheim is considering the sale of its U.S. generics unit Roxane Labs for as much as 2 billion euros ($2.36 billion), Bloomberg said, citing people with knowledge of the matter.
Boehringer Ingelheim
Breaking News
Generic drugmaker Actavis Plc and France's Sanofi SA are among the suitors for privately held Omega Pharma NV [COUCKO.UL], Bloomberg reported, citing people familiar with the matter.
California, US-based software developing company Accelrys has acquired Ireland-based software business Qumas in a deal valued at $50 million to expand its products expansion and client base.
Ben Venue Laboratories, a subsidiary of German Boehringer Ingelheim in the US, has engaged Bank of American Merill Lynch to advise it on a proposed sale of its sterile injectable drugs business.
Ben Venue was required by court to comply with good manufacturing standards set.
Subscribe to VCpost newsletter
Most Popular
- How to Get IRS Unclaimed Tax Refunds: Here's What to Do If You Think You Have Pending Payments
- SSDI Payment April 2024: Who Will Receive Social Security Benefits Today?
- Where's My Child Tax Credit 2024: When to Receive My Money After April 15 Tax Filing Deadline?
- Philippines Wants US, Japan to Fund Freight Railway Project After It Drops Funding Talks With China
- Canadian Family Receives Wrong Remains After Father Died While on Vacation in Cuba
- Samsung to Implement Six-Day Work Week for Executives Slammed by Critics 'Not Effective'
- Baltimore Sues Dali Cargo Ship Owner and Manager for Negligence That Led to Key Bridge Collapse
- American Millionaire Charged in Brutal Murders of Canadian Tycoon and His Partner in Dominica Denied Bail
